|
Nutraceuticals and Functional Foods |
|
|
1 | (22) |
|
|
|
|
1 | (1) |
|
Defining Nutraceuticals and Functional Foods |
|
|
2 | (1) |
|
Classifying Nutraceutical Factors |
|
|
3 | (1) |
|
Food and Nonfood Sources of Nutraceutical Factors |
|
|
4 | (1) |
|
Nutraceutical Factors in Specific Foods |
|
|
5 | (1) |
|
|
6 | (2) |
|
Classifying Nutraceutical Factors Based on Chemical Nature |
|
|
8 | (15) |
|
Isoprenoid Derivatives (Terpenoids) |
|
|
9 | (4) |
|
|
13 | (3) |
|
Carbohydrates and Derivatives |
|
|
16 | (3) |
|
Fatty Acids and Structural Lipids |
|
|
19 | (1) |
|
|
20 | (1) |
|
|
20 | (1) |
|
|
20 | (1) |
|
|
20 | (3) |
|
Isoflavones: Source and Metabolism |
|
|
23 | (32) |
|
|
|
Food Chemistry of Isoflavones |
|
|
23 | (9) |
|
|
32 | (11) |
|
Isoflavones in Soy Ingredients (including Soybeans) |
|
|
32 | (2) |
|
|
34 | (2) |
|
Soy Isoflavone Bioavailability |
|
|
36 | (1) |
|
Major Sites of Action of Isoflavones |
|
|
36 | (1) |
|
Health Beneficial Potential of Isoflavones |
|
|
37 | (1) |
|
Toxicology of Isoflavones |
|
|
38 | (2) |
|
Interactions of Isoflavones with Estrogen Receptors --- Key Sites of Action? |
|
|
40 | (1) |
|
Apparent Absorption and Relative Pharmacokinetics of Isoflavones |
|
|
41 | (1) |
|
Endogenous Biotransformation of Isoflavones |
|
|
42 | (1) |
|
Microbial Biotransformation and Apparent Degradation of Isoflavones |
|
|
43 | (2) |
|
|
43 | (1) |
|
General Significance of Gut Microbial Metabolism of Isoflavones |
|
|
44 | (1) |
|
|
45 | (10) |
|
|
45 | (1) |
|
|
45 | (10) |
|
Lycopene: Food Sources, Properties, and Health |
|
|
55 | (18) |
|
|
|
|
|
55 | (1) |
|
Dietary Sources of Lycopene |
|
|
56 | (1) |
|
Bioavailability, Biological Distribution, and Metabolism |
|
|
57 | (4) |
|
Absorption and Bioavailability |
|
|
57 | (2) |
|
Effect of Food Processing |
|
|
59 | (1) |
|
Factors Altering Absorption and Plasma Concentrations |
|
|
60 | (1) |
|
|
60 | (1) |
|
|
61 | (1) |
|
|
61 | (2) |
|
|
62 | (1) |
|
|
62 | (1) |
|
Lycopene and Chronic Disease |
|
|
63 | (4) |
|
|
63 | (1) |
|
|
64 | (1) |
|
|
65 | (1) |
|
|
66 | (1) |
|
|
66 | (1) |
|
|
67 | (1) |
|
|
67 | (6) |
|
|
67 | (6) |
|
Garlic: The Mystical Food in Health Promotion |
|
|
73 | (28) |
|
|
|
|
73 | (1) |
|
Garlic Composition and Chemistry |
|
|
74 | (2) |
|
|
76 | (1) |
|
|
76 | (3) |
|
|
79 | (8) |
|
Nitrosamine and Heterocyclic Amine Formation |
|
|
80 | (2) |
|
Carcinogen Activity Modulation |
|
|
82 | (1) |
|
Cell Cycle Arrest/Apoptosis |
|
|
83 | (1) |
|
|
84 | (1) |
|
|
84 | (1) |
|
Redox and Antioxidant Capacity |
|
|
85 | (1) |
|
Immunocompetence Ammunonutrition |
|
|
85 | (1) |
|
|
86 | (1) |
|
|
87 | (1) |
|
|
87 | (2) |
|
Cholesterol and Lipoproteins |
|
|
87 | (1) |
|
|
88 | (1) |
|
Plaque and Platelet Aggregation |
|
|
89 | (1) |
|
|
89 | (12) |
|
|
89 | (12) |
|
Grape Wine and Tea Polyphenols in the Modulation of Atherosclerosis and Heart Disease |
|
|
101 | (30) |
|
|
|
|
101 | (2) |
|
|
103 | (6) |
|
Chemical Background and Nomenclature |
|
|
103 | (1) |
|
Polyphenols in Wines and Grapes |
|
|
104 | (2) |
|
|
106 | (1) |
|
Absorption and Metabolism of Polyphenols |
|
|
107 | (2) |
|
Epidemiology of Polyphenols and Atherosclerosis |
|
|
109 | (1) |
|
Etiology of Atherosclerosis |
|
|
110 | (1) |
|
Actions of Polyphenols on Risk Factors Associated With CVD |
|
|
110 | (7) |
|
Effects on Cholesterol and Lipids |
|
|
110 | (1) |
|
General Antioxidant Effects |
|
|
110 | (2) |
|
|
112 | (3) |
|
Vasodilatory and Nitric Oxide-Related Effects |
|
|
115 | (1) |
|
|
115 | (1) |
|
Atherosclerosis and Inflammation |
|
|
116 | (1) |
|
Potential Adverse Effects of Polyphenols |
|
|
117 | (1) |
|
|
118 | (13) |
|
Significance of Polyphenols in CVD and Health |
|
|
118 | (1) |
|
|
119 | (1) |
|
|
120 | (11) |
|
Dietary Fiber and Coronary Heart Disease |
|
|
131 | (14) |
|
|
|
|
Dietary Fiber Classification and Food Sources |
|
|
131 | (3) |
|
Physical and Physiological Properties of Fiber |
|
|
134 | (2) |
|
Relationship between Cholesterol Levels and CHD |
|
|
136 | (5) |
|
Role of Fiber in Reducing Serum Cholesterol |
|
|
136 | (2) |
|
Mechanisms for Lowering of Serum Cholesterol by Fiber |
|
|
138 | (2) |
|
Other Relevant Considerations for Fiber and CHD Risk |
|
|
140 | (1) |
|
Fiber as Adjunct Therapy to Statin Medication |
|
|
140 | (1) |
|
Health Claims Associated with Fiber and CHD |
|
|
141 | (4) |
|
|
142 | (3) |
|
Omega-3 Fish Oils and Lipoprotein Metabolism |
|
|
145 | (10) |
|
|
|
145 | (1) |
|
|
145 | (1) |
|
Effects of N-3 Fish Oils on Lipoproteins |
|
|
146 | (3) |
|
Hepatic Production of VLDL |
|
|
146 | (1) |
|
Intestinal Production of Chylomicrons |
|
|
147 | (1) |
|
Lipolysis of Triglyceride-Rich Lipoproteins |
|
|
148 | (1) |
|
|
149 | (1) |
|
|
149 | (1) |
|
Specific Effects of Individual N-3 Fatty Acids |
|
|
149 | (1) |
|
Potential Adverse Effects of Fish Oils: Lipid Peroxidation |
|
|
149 | (1) |
|
Fish Oils as Combination Therapy for Hyperlipidemia |
|
|
150 | (1) |
|
|
150 | (5) |
|
|
150 | (5) |
|
Omega-3 Fish Oils and Insulin Resistance |
|
|
155 | (10) |
|
|
Clinical Indications for n-3 Fish Oils in Diabetes |
|
|
155 | (1) |
|
Maintenance of Glucose Homeostasis |
|
|
156 | (1) |
|
Effects of n-3 Fish Oils on Glycemic Control |
|
|
156 | (2) |
|
Effects of n-3 Fish Oils on Pancreatic Insulin Secretion |
|
|
158 | (1) |
|
Effects of n-3 Fish Oils on Hepatic Glucose Production |
|
|
158 | (1) |
|
Effects of n-3 Fish Oils on Peripheral Insulin Action |
|
|
158 | (1) |
|
Effects of n-3 Fish Oils on Adipokines |
|
|
159 | (1) |
|
|
159 | (6) |
|
|
160 | (5) |
|
Antioxidant Vitamin and Phytochemical Content of Fresh and Processed Pepper Fruit (Capsicum annuum) |
|
|
165 | (28) |
|
|
|
|
165 | (1) |
|
Fruits and Vegetables for Disease Prevention |
|
|
166 | (1) |
|
|
166 | (5) |
|
Effects of Postharvest Handling and Processing on Ascorbic Acid Content |
|
|
170 | (1) |
|
|
171 | (3) |
|
Postharvest Handling and Effect of Processing on Flavonoid Content |
|
|
173 | (1) |
|
|
174 | (2) |
|
Effect of Processing on Tocopherol Content of Peppers |
|
|
174 | (2) |
|
|
176 | (6) |
|
Effects of Postharvest Handling and Processing on Carotenoid Content |
|
|
180 | (2) |
|
|
182 | (11) |
|
Effects of Postharvest Handling and Processing |
|
|
185 | (1) |
|
|
185 | (8) |
|
Osteoarthritis: Nutrition and Lifestyle Interventions |
|
|
193 | (30) |
|
|
|
|
193 | (1) |
|
|
194 | (1) |
|
|
194 | (1) |
|
|
194 | (1) |
|
|
194 | (1) |
|
|
194 | (1) |
|
|
195 | (5) |
|
|
195 | (1) |
|
|
195 | (1) |
|
|
195 | (1) |
|
|
196 | (1) |
|
|
196 | (1) |
|
Sports Participation and Trauma |
|
|
196 | (3) |
|
|
199 | (1) |
|
|
199 | (1) |
|
Nutritional Factors --- Vitamin Supplements |
|
|
199 | (1) |
|
|
200 | (14) |
|
Nonpharmacological Treatments |
|
|
200 | (7) |
|
Pharmacological Treatments |
|
|
207 | (1) |
|
|
208 | (6) |
|
Lifestyle and Nutritional Interventions --- The Whole Picture |
|
|
214 | (1) |
|
|
214 | (9) |
|
|
215 | (8) |
|
Omega-3 Fatty Acids, Mediterranean Diet, Probiotics, Vitamin D, and Exercise in the Treatment of Rheumatoid Arthritis |
|
|
223 | (24) |
|
|
|
223 | (1) |
|
|
224 | (3) |
|
|
224 | (1) |
|
|
225 | (1) |
|
|
225 | (2) |
|
|
227 | (1) |
|
|
227 | (4) |
|
|
227 | (1) |
|
|
227 | (1) |
|
|
228 | (1) |
|
|
228 | (2) |
|
|
230 | (1) |
|
|
231 | (5) |
|
Nonpharmacological Treatment |
|
|
231 | (1) |
|
Pharmacological Treatment |
|
|
232 | (1) |
|
|
232 | (1) |
|
|
233 | (1) |
|
|
234 | (1) |
|
|
235 | (1) |
|
|
235 | (1) |
|
Supplementation Strategies |
|
|
236 | (1) |
|
|
236 | (11) |
|
|
237 | (10) |
|
Skeletal Effects of Soy Isoflavones in Humans: Bone Mineral Density and Bone Markers |
|
|
247 | (22) |
|
|
|
247 | (1) |
|
Epidemiologic Perspective |
|
|
248 | (3) |
|
|
248 | (1) |
|
Caucasian vs. Asian Populations: Bone Density and Fractures |
|
|
249 | (1) |
|
Soy Intake, Bone Density, and Fractures |
|
|
249 | (2) |
|
Current and Potential Alternative Treatments for Osteoporosis |
|
|
251 | (7) |
|
Estrogen Therapy/Hormone Therapy |
|
|
251 | (1) |
|
|
251 | (1) |
|
|
251 | (1) |
|
|
252 | (1) |
|
Selective Estrogen Receptor Modulators (SERMs) |
|
|
252 | (1) |
|
Soy Isoflavones: Potential Alternative for Osteoporosis Prevention? |
|
|
253 | (1) |
|
Protein and Soy Isoflavone Intake in Relation to Calcium Homeostasis |
|
|
253 | (1) |
|
Soy Isoflavones and Bone Mineral Density: Prospective Studies |
|
|
254 | (2) |
|
Biochemical Markers of, Bone in Response to Soy Isoflavones |
|
|
256 | (2) |
|
Summary and Current State of Understanding |
|
|
258 | (1) |
|
Gaps in Knowledge/Future Research Directions |
|
|
259 | (10) |
|
|
260 | (9) |
|
Applications of Herbs to Functional Foods |
|
|
269 | (16) |
|
|
|
|
269 | (1) |
|
|
270 | (1) |
|
Herbs as Ingredients in Functional Foods |
|
|
270 | (2) |
|
|
270 | (1) |
|
|
271 | (1) |
|
|
271 | (1) |
|
Effect of Processing Dilemma |
|
|
271 | (1) |
|
|
272 | (1) |
|
Interactions with Drugs Dilemma |
|
|
272 | (1) |
|
Label Statements and Claims |
|
|
272 | (1) |
|
Actions and Evidence of Herbal Efficacy |
|
|
273 | (7) |
|
|
273 | (4) |
|
|
277 | (1) |
|
|
277 | (1) |
|
|
278 | (1) |
|
|
279 | (1) |
|
|
279 | (1) |
|
|
280 | (1) |
|
|
280 | (5) |
|
|
281 | (4) |
|
Conjugated Linoleic Acids: Biological Actions and Health |
|
|
285 | (12) |
|
|
|
|
285 | (1) |
|
Absorption, Metabolism, and Body Weight |
|
|
286 | (1) |
|
|
286 | (1) |
|
|
286 | (1) |
|
Body Weight and Composition |
|
|
287 | (1) |
|
|
287 | (4) |
|
|
287 | (1) |
|
|
288 | (1) |
|
Inflammation and Immune Function |
|
|
289 | (1) |
|
|
290 | (1) |
|
|
290 | (1) |
|
|
291 | (1) |
|
|
291 | (1) |
|
|
291 | (6) |
|
|
292 | (5) |
|
Olive Oil and Health Benefits |
|
|
297 | (12) |
|
|
|
|
297 | (1) |
|
Nutritional Components of Olives |
|
|
298 | (1) |
|
|
298 | (2) |
|
|
300 | (3) |
|
Fatty Acids in the Mediterranean Diet |
|
|
300 | (1) |
|
Other Olive Constituents and Their Effects |
|
|
300 | (1) |
|
Olives as Sources of Antioxidants |
|
|
301 | (1) |
|
Olive Oil and Inflammation |
|
|
302 | (1) |
|
Hypertension and Olive Oil Consumption |
|
|
303 | (1) |
|
|
303 | (2) |
|
Breast Cancer and Olive Oil |
|
|
303 | (1) |
|
Prostate Cancer and Olive Oil |
|
|
304 | (1) |
|
Other Cancers and Olive Oil |
|
|
304 | (1) |
|
Summary and Future Need for Cancer Research and Olive Oil |
|
|
305 | (1) |
|
Other Disease Conditions and Olive Oil |
|
|
305 | (1) |
|
Summary of a Consensus Report |
|
|
305 | (1) |
|
|
305 | (4) |
|
|
306 | (3) |
|
The Role of α-and γ-Tocopherols in Health |
|
|
309 | (26) |
|
|
|
309 | (1) |
|
|
310 | (1) |
|
|
311 | (3) |
|
|
311 | (2) |
|
|
313 | (1) |
|
|
313 | (1) |
|
|
313 | (1) |
|
|
314 | (2) |
|
|
314 | (1) |
|
|
315 | (1) |
|
Human Requirements and Dietary Intake |
|
|
316 | (1) |
|
|
316 | (3) |
|
|
316 | (2) |
|
|
318 | (1) |
|
|
318 | (1) |
|
|
319 | (1) |
|
|
319 | (1) |
|
α-and γ-Tocopherol Interactions with Vitamin C |
|
|
320 | (1) |
|
Role in Chronic Disease Prevention |
|
|
320 | (4) |
|
|
321 | (1) |
|
|
322 | (1) |
|
|
322 | (1) |
|
|
323 | (1) |
|
|
323 | (1) |
|
|
324 | (1) |
|
|
324 | (11) |
|
|
325 | (1) |
|
|
325 | (10) |
|
Probiotics and Prebiotics |
|
|
335 | (18) |
|
|
|
335 | (3) |
|
|
335 | (2) |
|
Probiotic Products on the Market |
|
|
337 | (1) |
|
|
338 | (1) |
|
Microbiology of the Gastrointestinal Tract |
|
|
339 | (2) |
|
|
341 | (5) |
|
|
341 | (1) |
|
|
341 | (1) |
|
|
342 | (1) |
|
|
343 | (1) |
|
|
343 | (1) |
|
|
344 | (1) |
|
A Vehicle for Other Nutrients |
|
|
344 | (1) |
|
|
344 | (1) |
|
|
345 | (1) |
|
|
346 | (1) |
|
Fermented Vegetables and Other Foods |
|
|
346 | (1) |
|
The Future for Probiotics and Prebiotics |
|
|
347 | (6) |
|
|
347 | (6) |
|
Exopolysaccharides from Lactic Acid Bacteria: Food Uses, Production, Chemical Structures, and Health Effects |
|
|
353 | (20) |
|
|
|
|
|
353 | (1) |
|
Exopolysaccharides in Foods |
|
|
354 | (4) |
|
|
354 | (2) |
|
Factors Influencing the Production of Exopolysaccharides by Lactic Acid Bacteria |
|
|
356 | (1) |
|
|
356 | (1) |
|
Effect of Growth Media on Exopolysaccharide Production |
|
|
356 | (2) |
|
Interactions between Strains |
|
|
358 | (1) |
|
Effect of Fermentation Technology |
|
|
358 | (1) |
|
Chemical Structure of Exopolysaccharides |
|
|
358 | (1) |
|
Methods of Structural Characterization |
|
|
358 | (1) |
|
Health Benefits of Exopolysaccharides |
|
|
359 | (5) |
|
|
359 | (3) |
|
|
362 | (1) |
|
|
362 | (1) |
|
Cholesterol Digestion and Metabolism Effects |
|
|
363 | (1) |
|
|
363 | (1) |
|
Other Uses of Exopolysaccharides |
|
|
364 | (1) |
|
|
364 | (9) |
|
|
365 | (8) |
|
Omega-3 Fatty Acids, Tryptophan, B Vitamins, SAMe, and Hypericum in the Adjunctive Treatment of Depression |
|
|
373 | (18) |
|
|
|
|
373 | (1) |
|
|
374 | (2) |
|
|
376 | (1) |
|
|
376 | (1) |
|
|
376 | (1) |
|
|
377 | (4) |
|
Gender and Biological Factors |
|
|
377 | (2) |
|
|
379 | (1) |
|
|
380 | (1) |
|
|
381 | (5) |
|
|
381 | (1) |
|
Adjunctive Nutritional Regimens |
|
|
381 | (5) |
|
|
386 | (5) |
|
|
386 | (5) |
|
Protein as a Functional Food Ingredient for Weight Loss and Maintaining Body Composition |
|
|
391 | (18) |
|
|
|
|
Macronutrient Levels and Weight Loss |
|
|
392 | (1) |
|
|
392 | (1) |
|
|
393 | (1) |
|
Roles of Amino Acids and Proteins |
|
|
393 | (2) |
|
|
395 | (1) |
|
|
396 | (1) |
|
Protein Digestion and Absorption |
|
|
397 | (1) |
|
|
397 | (1) |
|
BCAAs ---Specifically, Leucine and Weight Loss |
|
|
398 | (1) |
|
Protein and Glycemic Control |
|
|
398 | (1) |
|
|
399 | (1) |
|
Weight Loss and Energy Intake |
|
|
399 | (1) |
|
|
400 | (1) |
|
|
401 | (1) |
|
|
401 | (1) |
|
Protein, Exercise, and Weight Loss |
|
|
402 | (1) |
|
|
402 | (7) |
|
|
403 | (6) |
|
Nutraceuticals and Inflammation in Athletes |
|
|
409 | (12) |
|
|
|
|
|
409 | (1) |
|
Exercise and Inflammatory Mediators |
|
|
410 | (1) |
|
|
410 | (2) |
|
Cell Membrane Fatty Acid Content |
|
|
412 | (1) |
|
|
412 | (1) |
|
Omega-3 Fatty Acids and Inflammatory Mediators |
|
|
413 | (1) |
|
|
413 | (1) |
|
Exercise and Overtraining Syndrome |
|
|
414 | (1) |
|
Combination of Glutamine and Omega-3 Supplementation |
|
|
415 | (1) |
|
|
415 | (6) |
|
|
416 | (5) |
|
Oxidative Stress and Antioxidant Requirements in Trained Athletes |
|
|
421 | (22) |
|
|
|
|
|
422 | (1) |
|
|
422 | (4) |
|
|
422 | (1) |
|
Reactive Oxygen Species and Oxygen-Derived Free Radicals |
|
|
422 | (1) |
|
|
423 | (1) |
|
Characteristics of Oxidative Stress |
|
|
423 | (1) |
|
|
423 | (1) |
|
|
424 | (1) |
|
Nonenzymatic Antioxidants |
|
|
424 | (1) |
|
Antioxidants as Prooxidants |
|
|
424 | (2) |
|
Exercise-Induced Oxidative Stress |
|
|
426 | (1) |
|
Evidence of Oxidative Stress in Exercise |
|
|
426 | (1) |
|
Mechanisms that May Increase ROS Production in Exercise |
|
|
427 | (2) |
|
|
427 | (1) |
|
|
428 | (1) |
|
Inflammation and Immunity |
|
|
428 | (1) |
|
|
429 | (1) |
|
|
429 | (1) |
|
|
429 | (1) |
|
Antioxidants and Exercise |
|
|
429 | (1) |
|
Up-Regulation of Endogenously Produced Antioxidant Enzymes |
|
|
430 | (1) |
|
Increased de Novo Production of Endogenous Antioxidant Molecules |
|
|
430 | (1) |
|
|
431 | (1) |
|
Antioxidant Manipulation, Oxidative Stress, and Exercise Performance |
|
|
431 | (1) |
|
Antioxidant Deficiency and Restriction |
|
|
432 | (1) |
|
|
433 | (1) |
|
|
433 | (2) |
|
|
435 | (8) |
|
|
435 | (8) |
|
Coenzyme Q10: A Functional Food with Immense Therapeutic Potential |
|
|
443 | (10) |
|
|
|
|
|
443 | (1) |
|
|
444 | (1) |
|
|
444 | (1) |
|
Treatment of Heart Disease with CoQ10 |
|
|
445 | (1) |
|
Methods for Detection of CoQ10 |
|
|
446 | (2) |
|
|
446 | (1) |
|
Instruments and Equipment |
|
|
446 | (1) |
|
|
447 | (1) |
|
Sample Preparation and Analysis |
|
|
447 | (1) |
|
|
447 | (1) |
|
|
448 | (5) |
|
|
450 | (3) |
|
Coffee as a Functional Beverage |
|
|
453 | (14) |
|
|
|
|
453 | (1) |
|
Introduction to Coffee and Caffeine |
|
|
454 | (1) |
|
|
454 | (1) |
|
Coffee and Caffeine in Weight Loss and Energy Expenditure |
|
|
455 | (1) |
|
Effects of Coffee (Caffeine) in the Brain and Body |
|
|
456 | (1) |
|
Exercise Performance with Coffee and Caffeine Consumption |
|
|
456 | (2) |
|
Health Related Issues in Coffee Consumption |
|
|
458 | (2) |
|
|
458 | (1) |
|
|
458 | (1) |
|
|
459 | (1) |
|
|
459 | (1) |
|
Conclusion and Closing Remarks |
|
|
460 | (7) |
|
|
462 | (5) |
|
Nutraceutical Stability Concerns and Shelf Life Testing |
|
|
467 | (18) |
|
|
|
467 | (1) |
|
Kinetic Modeling of Chemical Reactions |
|
|
468 | (11) |
|
Effect of Temperature on Stability |
|
|
472 | (2) |
|
Effect of Moisture on Stability |
|
|
474 | (3) |
|
Effect of Oxygen on Stability |
|
|
477 | (1) |
|
Effects of Ingredients on Stability |
|
|
477 | (2) |
|
Accelerated Shelf Life Testing |
|
|
479 | (1) |
|
|
480 | (5) |
|
|
481 | (4) |
|
Nutraceutical and Functional Food Application to Nonalcoholic Steatohepatitis |
|
|
485 | (18) |
|
|
|
|
485 | (1) |
|
|
486 | (1) |
|
|
486 | (1) |
|
|
486 | (4) |
|
|
487 | (1) |
|
|
488 | (1) |
|
Type II Diabetes Mellitus |
|
|
489 | (1) |
|
|
490 | (1) |
|
Other Conditions Associated with NASH |
|
|
490 | (1) |
|
|
490 | (1) |
|
Complementary Therapies in the Treatment of NASH |
|
|
490 | (8) |
|
Lifestyle Intervention: Weight Loss |
|
|
491 | (1) |
|
|
491 | (3) |
|
Nutritional Aspects of Treatment of NASH: Omega-3 Fatty Acids |
|
|
494 | (1) |
|
|
494 | (4) |
|
Is There a Liver Cleansing Diet? |
|
|
498 | (1) |
|
|
498 | (5) |
|
|
498 | (5) |
|
Marketing and Regulatory Issues for Functional Foods and Nutraceuticals |
|
|
503 | (14) |
|
|
|
504 | (1) |
|
Evolution of a Marketing Environment for Functional Foods and Nutraceuticals |
|
|
505 | (1) |
|
|
505 | (4) |
|
Appearance of Permissive Health Claims on Food Products |
|
|
506 | (1) |
|
Reaction and Institution of the NLEA |
|
|
506 | (1) |
|
Utilization of the FDA Modernization Act to Establish Health Claims |
|
|
507 | (1) |
|
Pursuit of Qualified Health Claims for Food Products |
|
|
508 | (1) |
|
Issues and Implications for Investment |
|
|
508 | (1) |
|
Future Issues: Nutrigenomics and Food Nanotechnology |
|
|
509 | (1) |
|
Introduction to Consumer Marketing Issues for Nutraceuticals and Functional Foods |
|
|
509 | (3) |
|
|
510 | (1) |
|
Brand Name Connects to Functional Advantage |
|
|
510 | (1) |
|
Consumer Education Required |
|
|
510 | (1) |
|
Avoid Information Overload |
|
|
511 | (1) |
|
Competitive Set Determined by Health Issue |
|
|
511 | (1) |
|
Importance of Nonverbal Messages |
|
|
511 | (1) |
|
|
511 | (1) |
|
Avoid Negative Advertising |
|
|
511 | (1) |
|
|
512 | (1) |
|
Exploit Corporate Heritage |
|
|
512 | (1) |
|
Dosage and Standardization |
|
|
512 | (1) |
|
|
512 | (1) |
|
Potential Product Positioning |
|
|
512 | (2) |
|
|
513 | (1) |
|
|
513 | (1) |
|
|
513 | (1) |
|
|
514 | (1) |
|
|
514 | (1) |
|
|
514 | (1) |
|
|
514 | (3) |
|
|
515 | (2) |
|
Obesity Policy: Opportunities for Functional Food Market Growth |
|
|
517 | (6) |
|
|
Emergence of Obesity as Major Public Health Issue |
|
|
517 | (1) |
|
Ingredients with Functional Potential to Mitigate Obesity |
|
|
518 | (2) |
|
|
518 | (1) |
|
|
518 | (1) |
|
|
519 | (1) |
|
Strategies for Qualified Health Claim Use |
|
|
520 | (1) |
|
Functional Foods and Obesity |
|
|
520 | (3) |
|
|
521 | (2) |
Index |
|
523 | |